Cite
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
MLA
Melanie Werner-Klein, et al. “Interleukin-6 Trans-Signaling Is a Candidate Mechanism to Drive Progression of Human DCCs during Clinical Latency.” Nature Communications, vol. 11, no. 1, Oct. 2020, pp. 1–18. EBSCOhost, https://doi.org/10.1038/s41467-020-18701-4.
APA
Melanie Werner-Klein, Ana Grujovic, Christoph Irlbeck, Milan Obradović, Martin Hoffmann, Huiqin Koerkel-Qu, Xin Lu, Steffi Treitschke, Cäcilia Köstler, Catherine Botteron, Kathrin Weidele, Christian Werno, Bernhard Polzer, Stefan Kirsch, Miodrag Gužvić, Jens Warfsmann, Kamran Honarnejad, Zbigniew Czyz, Giancarlo Feliciello, … Christoph A. Klein. (2020). Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency. Nature Communications, 11(1), 1–18. https://doi.org/10.1038/s41467-020-18701-4
Chicago
Melanie Werner-Klein, Ana Grujovic, Christoph Irlbeck, Milan Obradović, Martin Hoffmann, Huiqin Koerkel-Qu, Xin Lu, et al. 2020. “Interleukin-6 Trans-Signaling Is a Candidate Mechanism to Drive Progression of Human DCCs during Clinical Latency.” Nature Communications 11 (1): 1–18. doi:10.1038/s41467-020-18701-4.